Skip to content

Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)

Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03218319
Acronym
VAPANCR
Enrollment
200
Registered
2017-07-14
Start date
2017-07-31
Completion date
2018-12-31
Last updated
2017-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Nephrectomy, Renal Cancer

Brief summary

This study evaluates the impact of nephrectomy in renal cancer on blood pressure and renal function. The patients will have a follow-up of their blood pressure and renal function until 6 months after their operation.

Interventions

BIOLOGICALRenin measurement

patients will have a blood sample for measuring renin activity

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Nephrectomy programmed for located renal cancer

Exclusion criteria

* Patients with metastatic renal cancer * Incapacity to use a self-measurement tensiometer * Patients treated for high blood pressure * Patients with laxative

Design outcomes

Primary

MeasureTime frameDescription
Blood pressure changeOne time before the operation and twice after : 1 month and 6 monthspreoperative and postoperative measurements of blood pressure

Secondary

MeasureTime frameDescription
Renal functionOne time before the operation and one after 6 monthspreoperative and postoperative measurements of renal function with measurements of renin activity and the glomerular filtration rate.
Cardiovascular riskA clinical exam will perform before the surgery and 1 month and 6 months afterStudy the occurence of cardiovascular risk after nephrectomy

Contacts

Primary ContactPierre Bigot
PiBigot@chu-angers.fr+332 41 35 64 94

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026